UK MHRA Outlines 'Safety Feature' Challenges Facing Wholesale Sector
Executive Summary
At a recent MHRA symposium, wholesalers were treated to a presentation on possible hurdles they may encounter as the EU Falsified Medicines Directive brings in a new product verification system from February next year.
You may also be interested in...
MHRA Explains Its Approach To New 'Safety Features' In 2019
The MHRA has set out its position on those aspects of the new “safety feature” rules for prescription drugs where member states have flexibility to choose their options, such as the information to be included in the “unique identifier” and the conditions for “checking out” medicines from the verification system. The European Medicines Verification System is being introduced as part of the EU Falsified Medicines Directive.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.